Answers are grounded in this paper and cite their sources.
Non-small cell lung cancer (NSCLC) is the most common cancer, causing death and disability. Targeted therapy and immunotherapy have had an increasing role in the management of patients with advanced NSCLC. These treatments can produce an excellent curative effect, but the side effects should not be ignored. Skin toxicities such as papulopustular eruption, severe desquamation, and paronychia have a high incidence, seriously affecting patients’ quality of life and even interrupting treatment. Early recognition and adequate management are critical to prevent exacerbation of the lesions. This review describes the common skin toxicities related to targeted therapy and immunotherapy for NSCLC, summarizes the updated research progress of the mechanism, and proposes appropriate treatment and counseling for optimized management.
No takes yet. Share an insight, caveat, or question.
Min Zhang (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: